Ric Magnuson, former interim executive vice president and CFO of Vancouver, Wash.-based PeaceHealth, has joined the system’s board of directors, according to a Sept. 8 news release. Mr. Magnuson served in the interim role with PeaceHealth from June 2025 to…
The Latest
Babatope Fatuyi, MD, has been named chief health innovation officer at UTHealth Houston. Dr. Fatuyi previously served as chief medical information officer at the academic health center. He announced the leadership transition in a Sept. 8 LinkedIn post. In the…
Hattiesburg, Miss.-based Forrest Health has rebranded as Forrest, bringing its hospitals, clinics and other care sites under one unified name and visual identity. The health system unveiled the new brand Sept. 8, according to a news release. The new identity…
Patients 70 years and older make up 13% of lung transplant recipients worldwide, up from 1% in 2004, a recent study presented at the European Respiratory Society Congress 2026 found. The research, led by Christian Benden, MD, MBA, director of…
As Generation Z takes up a growing share of the healthcare workforce, health system leaders are putting greater focus on helping early-career employees build the interpersonal skills, connections and career pathways they need to succeed. Human resources executives told Becker’s…
More than a third (36%) of healthcare respondents said they lacked direction at work because their organizations had too few managers, according to Korn Ferry’s 2026 global workforce survey. The survey, now in its third year, included more than 16,000…
Aledade named Sashi Moodley, MD, as chief medical officer and Kim Wittman as chief people officer, the Bethesda, Md.-based value-based care company said in a Sept. 9 news release. Aledade said it will consolidate clinical strategy across its network of…
Obstetric services became increasingly unavailable at U.S. hospitals from 2010 through 2024, with 718 hospitals losing services through obstetric unit or hospital closures, according to a September 2026 report from the University of Minnesota Rural Health Research Center. Here are…
Roivant’s experimental lung disease drug mosliciguat produced a 56.3% placebo-adjusted reduction in pulmonary vascular resistance in a phase 2 trial of patients with pulmonary hypertension associated with interstitial lung disease, the highest PVR reduction reported in a randomized controlled pulmonary…
An AI-generated drug, rentosertib, being developed for idiopathic pulmonary fibrosis was associated with reductions in predicted biological age across six proteomic aging clocks, according to a study published Sept. 7 in Nature Biotechnology. Here are six things to know: